FasL gene knock-down therapy enhances the antiglioma immune response.
Malignant glioma is a lethal form of brain cancer that is very difficult to treat. The aggressive behavior of these neoplasms and their limited responsiveness to therapy has been attributed in part to the ability of these tumors to evade the immune system. Gliomas, like many other solid tumors, express components of numerous immune escape mechanisms, including immunosuppressive proteins such as TGF-beta, IL-10, and FasL. Here, we show that FasL expression can support the growth of experimental intracranial glioma. We show that FasL is readily detected in human glioblastoma multiforme clinical specimens. FasL was found to be expressed by three well-characterized rat glioma cell lines (9L, F98, and C6) and glioma cell-derived FasL mediated the death of phytohemagglutinin-stimulated Jurkat T-lymphocytes when cocultured with glioma cells in vitro. We asked if inhibiting 9L-derived FasL altered the growth of experimental glioma. FasL expression knockdown using shRNA reduced the growth of subcutaneous and intracranial 9L gliomas by approximately 50% in immune competent Fisher 344 rats. In contrast, FasL expression knockdown had no affect on the growth of intracranial 9L glioma in T-cell deficient athymic rats. Intracranial tumors derived from FasL knockdown 9L glioma cells contained up to 3-fold more tumor infiltrating T-cells than tumors derived from control 9L cells. These results demonstrate that down-regulating FasL expression and/or function in glial malignancies can enhance T-cell tumor infiltration and inhibit tumor growth. The findings suggest that targeting endogenous FasL in glial malignancies could enhance the efficacy of emerging immune-based treatment strategies.
Jansen
Timothy
T
Departments of Neurosurgery, Fondazione IRCCS Istituto Nazionale C Besta, Milan, Italy.
Tyler
Betty
B
Mankowski
Joseph L
JL
Recinos
Violette Renard
VR
Pradilla
Gustavo
G
Legnani
Federico
F
Laterra
John
J
Olivi
Alessandro
A
D000818:Animals; D001932:Brain Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D053222:Fas Ligand Protein / Q000235:genetics* / Q000276:immunology; D055785:Gene Knockdown Techniques; D015316:Genetic Therapy / Q000379:methods*; D005910:Glioma / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D006801:Humans; D015151:Immunoblotting; D051381:Rats; D011916:Rats, Inbred F344; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019139:Tumor Escape / Q000235:genetics / Q000276:immunology; D023041:Xenograft Model Antitumor Assays
D053222:Fas Ligand Protein
Br J Cancer. 2007 Sep 3;97(5):637-45
17667919
Cancer Res. 1993 Jan 15;53(2):329-33
8417826
Cytokine Growth Factor Rev. 2008 Feb;19(1):65-77
18061513
Int J Oncol. 2007 Jan;30(1):273-81
17143538
Br J Cancer. 2001 Sep 28;85(7):1047-54
11592778
Ann Oncol. 2005;16 Suppl 1:i64-5
15888760
Carcinogenesis. 2007 May;28(5):1067-73
17183065
Cancer Res. 2009 Feb 1;69(3):855-62
19141642
Mol Cancer Res. 2008 Jan;6(1):139-50
18234969
Cancer Res. 2006 Jun 1;66(11):5527-36
16740684
J Neurosurg. 2002 Mar;96(3):580-4
11883844
J Neuroimmunol. 2002 Aug;129(1-2):10-7
12161015
Brain Res. 1996 Aug 26;731(1-2):161-70
8883866
J Immunol. 2003 Oct 15;171(8):3947-54
14530312
Electrophoresis. 2001 Jun;22(10):1887-93
11465484
Science. 1995 Nov 17;270(5239):1189-92
7502042
Brain Pathol. 1997 Jul;7(3):863-9
9217971
Chem Immunol Allergy. 2007;92:140-154
17264490
Am J Pathol. 2006 Oct;169(4):1415-26
17003496
Exp Cell Res. 1998 Oct 10;244(1):302-9
9770373
Annu Rev Genomics Hum Genet. 2002;3:101-28
12142355
Cytokine Growth Factor Rev. 1996 Jun;7(1):93-102
8864357
J Clin Invest. 1997 Mar 15;99(6):1173-8
9077524
Cancer Res. 1998 Jan 15;58(2):302-9
9443409
Oncogene. 2009 Feb 5;28(5):721-33
19029949
Crit Rev Oncog. 1993;4(5):493-540
8241322
Cancer Immunol Immunother. 2007 Jan;56(1):48-59
16612596
Cancer Immunol Immunother. 2009 Feb;58(2):259-70
18594817
Hepatol Res. 2003 Dec;27(4):309-314
14662119
Cancer Res. 2005 Jun 15;65(12):5248-55
15958570